Journal
ACTA OTORRINOLARINGOLOGICA ESPANOLA
Volume 65, Issue 6, Pages 346-354Publisher
ELSEVIER ESPANA SLU
DOI: 10.1016/j.otorri.2014.02.014
Keywords
Epistaxis; Dabigatran; Adverse effects
Categories
Ask authors/readers for more resources
Objective: Dabigatran is a new non-vitamin K antagonist (VKA) anticoagulant with anti-thrombin action, with supposedly fewer haemorrhagic complications. However, there are actually no established agents to reverse its effect, nor specific coagulation time tests for monitoring it. Materials and methods: An observational prospective study was developed, noting epidemiological, clinical and therapeutic features among subjects with epistaxis treated with dabigatran. Results were compared with a group of epistaxis cases of individuals under anticoagulant therapy with VKA (acenocoumarol) and a control group without anticoagulation. Results: Since its inclusion in our health system almost 3 years ago, 19 patients with epistaxis and concomitant use of dabigatran have been attended at the Emergency Unit in our hospital, as against 59 under VKA therapy and 144 without anticoagulation, with a mean admittance rate of 26%, 28% and 14%, respectively. In 3 out of 5 individuals admitted due to dabigatran treatment, previously unobserved renal failure was detected. Blood transfusion was needed in 80% of patients using dabigatran, 58% using VKA and 23% without anticoagulation. Invasive procedures to control nosebleed were required in 80%, 35% and 21%, respectively. Although haemorrhagic risk was lower in dabigatran cases, they showed the longest stay in the hospital when compared to the other groups. Conclusions: With dabigatran, there are fewer cases of severe epistaxis than with acenocoumarol, but controlling them is more difficult. (C) 2013 Elsevier Espana, S.L.U. and Sociedad Espanola de Otorrinolaringologia y Patologia Cervico-Facial. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available